


For more information visit www.iom.edu/vaccineadverseeffects

Adverse Effects of Vaccines

Evidence and Causality



Immunizations are a cornerstone of the nation's efforts to protect people from a host of infectious diseases. As required by the Food and Drug Administration, vaccines are tested for safety before they enter the market, and their performance is continually evaluated to identify any risks that might appear over time.

Vaccines are not free from side effects, or "adverse effects," but most are very rare or very mild. Importantly, some adverse health problems following a vaccine may be due to coincidence and are not caused by the vaccine. As part of the evaluation of vaccines over time, researchers assess evidence to determine if adverse events following vaccination are causally linked to a specific vaccine, and if so, they are referred to as adverse effects. Under the National Childhood Vaccine Injury Act of 1986, Congress established the National Vaccine Injury Compensation Program (VICP) to provide compensation to people injured by vaccines. Anyone who thinks they or a family member—often a child—has been injured can file a claim.

The Health Resources and Services Administration (HRSA), the agency within the Department of Health and Human Services that administers VICP, can use evidence that demonstrates a causal link between an adverse event and a vaccine to streamline the claim process. As such, HRSA asked the Institute of Medicine (IOM) to review a list of adverse events associated with vaccines covered by VICP and to evaluate the scientific evidence about the event–vaccine relationship. The vaccines covered by VICP include all vaccines recommended by the Centers for Disease Control and Prevention (CDC) for routine administration in children. Adults who experience an adverse event following one of these childhood vaccines also are covered by the program. HRSA

As part of the evaluation of vaccines over time, researchers assess evidence to determine if adverse events following vaccination are causally linked to a specific vaccine, and if so, they are referred to as adverse effects.

asked the IOM to review 8 of the 12 covered vaccines. These eight are the varicella zoster vaccine (used against chickenpox); the influenza vaccines (except for the H1N1 influenza vaccine distributed in 2009); the hepatitis B vaccine; the human papillomavirus (HPV) vaccine; the measles, mumps, and rubella (MMR) vaccine; the hepatitis A vaccine; the meningococcal vaccines, and tetanus-containing vaccines that do not carry the whole-cell pertussis component.

Examining the Evidence

The adverse events selected by HRSA for IOM review are ones for which people have submitted claims—successful or not—to VICP. The committee appointed to this study was not asked to assess the benefits or effectiveness of vaccines but only the risk of specific adverse events. Its conclusions reflect the best evidence available at the time. Some of the adverse events the committee examined already are accepted in the medical community, but they are minor or manageable—for example, a sudden allergic reaction called anaphylaxis that can follow the administration of some vaccines.

In its report, the committee explains its process for evaluating the list of adverse events and provides a set of 158 causality conclusions. The committee examined two types of evidence: epidemiologic evidence, which derives from studies of populations, and mechanistic evidence, which draws from biological and clinical studies. The committee evaluated each scientific article for its strengths and weaknesses and then assigned a “weight of evidence” ranking to both the epidemiologic and mechanistic bodies of studies.

The committee considered the weights of evidence and then reached a conclusion about the causal relationship between each vaccine and adverse health problem pairing. The committee began from a position of neutrality, presuming neither causation nor lack of causation, and moved from that position only when the combination of evidence suggested a more definitive assessment regarding causation. The figure pro-

vides an explanation of how the evidence influenced the causality conclusions.

Based on the totality of the evidence, the committee assigned each relationship to one of four categories of causation in which the evidence:

- convincingly supports a causal relationship;
- favors acceptance of a causal relationship;
- favors rejection of a causal relationship; or
- is inadequate to accept or reject a causal relationship.

The committee did not use a category to designate evidence that convincingly supports no causal relationship, because it is virtually impossible to prove the absence of a very rare relationship with the same certainty that is possible to establish the presence of one.

Evidence Convincingly Supports a Causal Relationship

The committee concludes that the evidence convincingly supports a causal relationship between some vaccines and some adverse events.

As a live vaccine, the varicella zoster vaccine is linked to four specific adverse events, all due to infection from the vaccine virus strain:

- Disseminated varicella infection (widespread chickenpox rash shortly after vaccination)
- Disseminated varicella infection with subsequent infection resulting in pneumonia, meningitis, or hepatitis in individuals with demonstrated immunodeficiencies
- Vaccine strain viral reactivation (appearance of chickenpox rash months to years after vaccination)
- Vaccine strain viral reactivation with subsequent infection resulting in meningitis or encephalitis (inflammation of the brain)

The MMR vaccine is linked to a disease called measles inclusion body encephalitis, which in very rare cases can affect people whose immune

The committee began from a position of neutrality, presuming neither causation nor lack of causation, and moved from that position only when the combination of evidence suggested a more definitive assessment regarding causation.

systems are compromised and usually occurs within a year of acute measles infection or vaccination. The MMR vaccine also is linked to febrile seizures, which are a type of seizure that occurs in infants and young children in association with fever. Febrile seizures are generally benign and hold no long-term consequences.

Six types of vaccines—MMR, varicella zoster, influenza, hepatitis B, meningococcal, and tetanus-containing vaccines—are linked to anaphylaxis.

The committee also found convincing evidence of a causal relationship between injection of vaccine, independent of the antigen involved, and two types of adverse events, including syncope, or fainting, and deltoid bursitis, or frozen shoulder, characterized by shoulder pain and loss of motion.

Evidence Favors Acceptance of a Causal Relationship

The evidence favors acceptance of four vaccine–adverse event relationships. In these cases, the evidence is strong and generally suggestive, but not firm enough to be described as convincing. These relationships include:

- HPV vaccine and anaphylaxis;
- MMR vaccine and transient arthralgia (temporary joint pain) in female adults;
- MMR vaccine and transient arthralgia in children; and
- certain trivalent inactivated influenza vaccines used in Canada in some recent years

and a mild and temporary oculo-respiratory syndrome, which is characterized by conjunctivitis, facial swelling, and upper respiratory symptoms, including coughing and wheezing.

Evidence Favors Rejection of a Causal Relationship

The evidence favors rejection of five vaccine–adverse event relationships:

- MMR vaccine and autism
- MMR vaccine and type 1 diabetes
- DTaP (tetanus) vaccine and type 1 diabetes
- Inactivated influenza vaccine and Bell’s palsy (weakness of the facial nerve)
- Inactivated influenza vaccine and exacerbation of asthma or reactive airway disease episodes in children and adults

Evidence Inadequate to Accept or Reject a Causal Relationship

For the vast majority, (135 vaccine–adverse event pairs), the evidence is inadequate to accept or reject a causal relationship. In many cases, the adverse event being examined is an extremely rare condition, making it hard to study. In these cases, there was not adequate evidence to determine if the vaccine was or was not causally associated.



Committee to Review Adverse Effects of Vaccines

Ellen Wright Clayton (Chair)
Craig-Weaver Professor of Pediatrics; Director, Center for Biomedical Ethics and Society; Professor of Law; Vanderbilt University

Inmaculada B. Aban
Associate Professor, Department of Biostatistics, University of Alabama, Birmingham

Douglas J. Barrett
Professor, Departments of Pediatrics, Molecular Genetics & Microbiology, and Pathology, Immunology, & Laboratory Medicine at the University Of Florida College Of Medicine

Martina Bebin
Associate Professor of Neurology and Pediatrics, University of Alabama at Birmingham

Kirsten Bibbins-Domingo
Associate Professor and Attending Physician, University of California, San Francisco

Graham A. Colditz (Resigned August 2010)
Associate Director for Prevention and Control, Alvin J. Siteman Cancer, and Niess-Gain Professor in the School of Medicine, Department of Surgery, Washington University

Martha Constantine-Paton
Investigator, McGovern Institute for Brain Research; Professor of Biology, Department of Biology, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology

Deborah J. del Junco
Senior Epidemiologist and Associate Professor of Biostatistics, Epidemiology, and Research Design, University of Texas Health Science Center at Houston

Betty A. Diamond
Head, Center for Autoimmune and Musculoskeletal Disease, The Feinstein Institute for Medical Research, North Shore-LIJ Health System

S. Claiborne Johnston
Associate Vice Chancellor of Research; Director, Clinical and Translational Science, Institute Professor of Neurology and Epidemiology; Director, Neurovascular Disease and Stroke Center; University of California, San Francisco

Anthony L. Komaroff
Steven P. Simcox, Patrick A. Clifford, and James H. Higby Professor of Medicine; Senior Physician, Brigham and Women's Hospital; Harvard Medical School

B. Paige Lawrence
Associate Professor of Environmental Medicine; Associate Professor of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry

M. Louise Markert
Associate Professor of Pediatrics and Immunology, Division of Pediatric Allergy and Immunology, Department of Pediatrics, Duke University Medical Center

Ruby H.N. Nguyen (Resigned March 2010)
Assistant Professor, Division of Epidemiology and Community Health, University of Minnesota School of Public Health

Marc C. Patterson
Chair, Division of Child and Adolescent Neurology; Professor of Neurology, Pediatrics, and Medical Genetics; Director, Child Neurology Training Program, Mayo Clinic

Hugh A. Sampson
Professor of Pediatrics and Immunology; Dean for Translational Biomedical Sciences; Director of the Jaffe Food Allergy Institute, Mount Sinai School of Medicine

Pauline A. Thomas
Associate Professor, Department of Preventive Medicine and Community Health, New Jersey Medical School; and Associate Professor, School of Public Health, University of Medicine and Dentistry of New Jersey

Leslie P. Weiner
Richard Angus Grant, Sr. Chair in Neurology; Professor of Neurology and Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California

Study Staff

Kathleen Stratton
Study Director

Andrew Ford
Program Officer

Erin Rusch
Research Associate

Trevonne Walford
Research Assistant (from August 2009)

William McLeod
Senior Research Librarian

Hope Hare
Administrative Assistant

Amy Pryzbocki
Financial Associate

Rose Marie Martinez
Director, Board on Population Health and Public Health Practice

Study Sponsor

The Health Resources and Services Administration
The Centers for Disease Control and Prevention
The National Vaccine Program Office

Susceptibility

As some of the conclusions suggest, individuals with certain characteristics are more likely to suffer certain adverse effects from particular immunizations. Individuals who have serious immunodeficiencies are clearly at increased risk for specific adverse reactions to live viral vaccines, such as MMR and varicella vaccines. Thus, the committee was able at times to reach more limited conclusions for subgroups of the population.

Conclusion

In applying consistent standards across all the evidence, the committee found that some conclusions were easy to reach: the evidence was clear and consistent or, in the extreme, completely absent. Others required substantial discussion and debate.

The committee was not charged with making recommendations, and it did not pinpoint any particular areas for continued research. Much research already occurs to determine the safety of vaccines for the populations for whom they are recommended. However, there is much to learn about the human immune system, autoimmunity, and the effects of genetic variation, all of which may influence how people respond to vaccines.

Vaccines offer the promise of protection against a variety of infectious diseases. Despite much media attention and strong opinions from many quarters, vaccines remain one of the greatest tools in the public health arsenal. Certainly, some vaccines result in adverse effects that must be acknowledged. But the latest evidence shows that few adverse effects are caused by the vaccines reviewed in this report.

INSTITUTE OF MEDICINE
OF THE NATIONAL ACADEMIES

Advising the nation • Improving health

500 Fifth Street, NW
Washington, DC 20001

TEL 202.334.2352

FAX 202.334.1412

www.iom.edu

The Institute of Medicine serves as adviser to the nation to improve health.

Established in 1970 under the charter of the National Academy of Sciences, the Institute of Medicine provides independent, objective, evidence-based advice to policy makers, health professionals, the private sector, and the public.

Copyright 2011 by the National Academy of Sciences. All rights reserved.

For more information visit www.iom.edu/vaccineadverseeffects

Adverse Effects of Vaccines

Evidence and Causality

FIGURE

Strength of Evidence that Determined the Causality Conclusions

| EPIDEMIOLOGIC ASSESSMENT | | | | | | MECHANISTIC ASSESSMENT | | | | | CAUSALITY CONCLUSION | | | |
|--------------------------|-------------------------------------|---------------------------|--|---------|--------------|------------------------|---------------|---------------------------------------|------|---------|--------------------------------|------------------|-------------------|--------------------------------|
| High (increased risk) | High (decreased risk or no effect) | Moderate (increased risk) | Moderate (decreased risk or no effect) | Limited | Insufficient | Strong | Inter-mediate | Low-Inter-mediate | Weak | Lacking | Inadequate to Accept or Reject | Favors Rejection | Favors Acceptance | Convincingly Supports |
| High (increased risk) | | | | | | | | | | | | | | Convincingly Supports |
| | | | | | | Strong | | | | | | | | Convincingly Supports |
| | | Moderate (increased risk) | | | | | | | | | | | | Favors Acceptance |
| | | | | | | | Inter-mediate | | | | | | | Favors Acceptance |
| | High (decreased risk or no effect)* | | | | | | | | | | | | | Favors Rejection |
| | | | | | | | | | | | | | | Inadequate to Accept or Reject |
| | | | Moderate (decreased risk or no effect), Limited, or Insufficient** | | | | | | | | | | | Inadequate to Accept or Reject |
| | | | | | | | | Low-Intermediate, Weak, or Lacking*** | | | | | | Inadequate to Accept or Reject |

* Causality conclusion is favors rejection only if mechanistic assessment is **not** strong or intermediate.
 ** Causality conclusion is inadequate to accept or reject only if mechanistic assessment is **not** strong or intermediate.
 *** Causality conclusion is inadequate to accept or reject only if epidemiologic assessment is **not** high (increased risk), high (decreased risk or no effect), or moderate (increased risk).

TABLE: Summary of Causality Conclusions

| Vaccine | Adverse Event | Causality Conclusion |
|--------------------------|--|---------------------------------------|
| Varicella | Disseminated varicella infection (widespread chickenpox rash shortly after vaccination) | Convincingly Supports |
| Varicella | Disseminated varicella infection with subsequent infection resulting in pneumonia, meningitis, or hepatitis | Convincingly Supports ^a |
| Varicella | Vaccine strain viral reactivation (appearance of chickenpox rash months to years after vaccination) | Convincingly Supports |
| Varicella | Vaccine strain viral reactivation with subsequent infection resulting in meningitis or encephalitis (inflammation of the brain) | Convincingly Supports |
| MMR | Measles inclusion body encephalitis | Convincingly Supports ^{a, b} |
| MMR | Febrile seizures (a type of seizure that occurs in association with fever and is generally regarded as benign) | Convincingly Supports |
| MMR | Anaphylaxis (a very rare but sudden allergic reaction) | Convincingly Supports |
| Varicella | Anaphylaxis | Convincingly Supports |
| Influenza | Anaphylaxis | Convincingly Supports |
| Hepatitis B | Anaphylaxis | Convincingly Supports ^c |
| Tetanus Toxoid | Anaphylaxis | Convincingly Supports |
| Meningococcal | Anaphylaxis | Convincingly Supports |
| Injection-Related Event | Deltoid bursitis (frozen shoulder, characterized by shoulder pain and loss of motion) | Convincingly Supports |
| Injection-Related Event | Syncope (fainting) | Convincingly Supports |
| HPV | Anaphylaxis | Favors Acceptance |
| MMR | Transient arthralgia (temporary joint pain) in women | Favors Acceptance ^d |
| MMR | Transient arthralgia in children | Favors Acceptance |
| Influenza | Oculorespiratory syndrome (a mild and temporary syndrome characterized by conjunctivitis, facial swelling, and upper respiratory symptoms) | Favors Acceptance ^e |
| MMR | Autism | Favors Rejection |
| Influenza | Inactivated influenza vaccine and Bell's palsy (weakness or paralysis of the facial nerve) | Favors Rejection |
| Influenza | Inactivated influenza vaccine and asthma exacerbation or reactive airway disease episodes in children and adults | Favors Rejection |
| MMR | Type 1 diabetes | Favors Rejection |
| DT, TT, or aP containing | Type 1 diabetes | Favors Rejection |

^a The committee attributes causation to individuals with demonstrated immunodeficiencies.

^b The committee attributes causation to the measles component of the vaccine.

^c The committee attributes causation to yeast-sensitive individuals.

^d The committee attributes causation to the rubella component of the vaccine.

^e The committee attributes causation to two particular vaccines used in three particular years in Canada.

All other causality conclusions are the evidence is inadequate to accept or reject a causal relationship.